MedDataX Logo

Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations

NCT ID: NCT04765839

Last Updated: 2021-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-12

Study Completion Date

2021-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants. At baseline, 2 weeks and 4 weeks, the study team will survey participants to assess knowledge and attitudes about COVID-19 vaccines, including intention to be vaccinated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A cluster randomized trial with 80 participants from the social networks of 8 CLs will be conducted prior to widespread vaccine availability to the general public. Four CLs and social networks (cluster of 10 per network) will be randomly assigned to receive the intervention immediately or after a delay of 2 weeks. Intervention participants will be invited to a closed social media group on the platform of their choice. CLs, selected for trustworthiness within vulnerable populations, will disseminate community-informed COVID-19 vaccine messages to members of their social networks and engage in bidirectional communication with CEnR partners to refine messages. At baseline, 2 weeks and 4 weeks, participants will be surveyed to assess knowledge and attitudes about COVID-19 vaccines, including intention to be vaccinated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaccine Preventable Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

hesitancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants
Randomization outcomes will not be disclosed to participants.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm - Receives COVID-19 Vaccine messages

Group to receive COVID-19 Vaccine messages during the first two weeks of the study.

Group Type EXPERIMENTAL

Educational, culturally appropriate COVID-19 messages

Intervention Type OTHER

Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.

Delayed Intervention Arm

Group to receive COVID-19 Vaccine messages during the last two weeks of the study.

Group Type EXPERIMENTAL

Educational, culturally appropriate COVID-19 messages

Intervention Type OTHER

Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Educational, culturally appropriate COVID-19 messages

Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Self-identification within a CLs social network
* Age 18 or greater
* Functional internet access.

Exclusion Criteria

* Does not self-identify within a CLs social network
* Is under the age of 18
* Does not have functional internet access.
Minimum Eligible Age

18 Years

Maximum Eligible Age

101 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mark L Wieland

Chair, Community Internal Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark Mark

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-000205

Identifier Type: -

Identifier Source: org_study_id